Sequencing Through Multiple Lines of Therapy for mRCC
A panelist discusses how treatment sequencing decisions in RCC span multiple lines of therapy, incorporating various options like tivozanib, lenvatinib-everolimus combinations, and belzutifan, with careful consideration given to optimal dosing strategies, expected duration of therapy, anticipated response patterns, and the specific timing of each agent in the treatment journey, particularly in the post-ICI setting.
Video content above is prompted by the following:
- How are you sequencing these agents through multiple lines of therapy?
- Thinking beyond the patient case just reviewed, please discuss your preferred subsequent-line after a first-line ICI + ICI regimen?
- Would you have followed the sequence of therapies used for the patient described in this case?
- Are you using tivozanib in the second-line setting? If yes, in which patients?
- Are you using lenvatinib + everolimus in the post-ICI setting? If yes, in what line of therapy?
- How do you approach dosing? How long to you expect your patients to remain on therapy? What type of responses do you expect (depth, duration)?
- How are you using belzutifan in your practice?
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
